PYX-201 wins fast track status for patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who have progressed on platinum-based chemotherapy and an anti–PD-L1/PD-1 ...

[2] Good evidence exists for the use of anti-EGF receptor (EGFR) monoclonal antibody treatment as part of first-line combination chemotherapy including infusional 5-fluorouracil and for third-line ...

locally advanced head and neck squamous cell carcinoma (HNSCC) as neoadjuvant treatment, then continued as adjuvant treatment in combination with standard radiotherapy, with or without cisplatin ...

This designation is for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who have experienced disease progression after platinum-based ...

International Holding Company (IHC) has reported significant growth in its full-year 2024 financial results, underscoring its ability to drive strong performance and strategic portfolio management.

Most of the currently promising compound groups belong either to the class of EGFR inhibitors (e.g., cetuximab ... locally advanced HPV/p16-negative HNSCC tumors with or without the hypoxic ...

Keytruda's sBLA for LA-HNSCC treatment is under FDA priority review, with a decision expected by June 23. The KEYNOTE-689 trial showed significant improvements in event-free survival and major ...

1,2 In patients with resectable locally advanced HNSCC, the perioperative treatment regimen of pembrolizumab led to a statistically significant and clinically meaningful improvement in event-free ...

The Islamabad High Court (IHC) has declared Section 7 of the Finance Act 2015 void ab initio, declaring it contradictory to the Constitution, and struck it down along with all orders and actions ...